[323 Pages Report] The global personal genome testing market is forecast to be appraised at US$ 4,468 Million by 2032, up from US$ 1,545.5 Million in 2022, advancing at a CAGR of 10.1% during the forecast period.
| Attributes | Details |
|---|---|
| Personal Genome Testing Market Size (2022) | US$ 1,545.5 Million |
| Personal Genome Testing Market Size (2032) | US$ 4,468 Million |
| Personal Genome Testing Market CAGR (2022 to 2032) | 10.1% |
The advancements in the field of genetic testing, along with its wide usage in pharmacogenomics and toxicogenomic, drives the demands for personal genome testing. Increasing deployment of paternity testing, maternity testing, and prenatal testing promotes personal genome testing market growth.
The increased and developing awareness among healthcare professionals regarding the efficacy of these diagnostics owing to strong testing volumes ordered and managed by non-geneticists surges the adoption of personal genome testing.
Lifestyle-based and nutrition-based genetic tests are widely available for aiding diet and lifestyle plans among consumers, increasing demand for personal genome testing. The accuracy and reliable technology of genetic testing, and the growing awareness about its benefits, propels the personal genome testing market share.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
With the expansion of DTC genetic tests' application areas, the market share for personal genome testing increases. The market for personal genome testing is being expanded by businesses that provide DTC tests for use in continuing research, sports, nutrition, and other areas.
The range of services offered by genetic testing, such as data security, identification of ancestors, race and nature of family, increasing its usage in clinical practices, surges demand for personal genome testing.
The low cost value of genome testing across clinics, ranging from US$ 99 to US$ 2000, drives the demand for personal genome testing. Rising prevalence of genetic diseases related to genotype, phenotype, or mutation, and its need for detection and prevention propels the personal genome testing market growth.
The ability to detect genetic abnormalities in the early gestation period of 8 to 10 weeks surges the demand for personal genome testing. Growing R&D activities, along with government initiatives in the field, escalates the adoption of personal genome testing.
Increasing awareness and discoveries in the field of genetic testing, as well as the option to determine the sex of a fetus, broadens the personal genome testing market share. Descriptive information regarding analytical validity and clinical validity of the tests offered by the service provide, increases the demand for personal genome testing.
The requirement for identification and addressing of specific needs, personalized direct-to-consumer genetic tests, escalates the personal genome testing market size. Favorable reimbursement policies and increasing coverage for preventative genetic testing elevate the personal genome testing market share.
Due to the shortage of trained professionals, end users face significant issues in analyzing genomic data, hindering the personal genome testing market growth. Rigid regulatory requirements for product approvals are expected to hamper the demand for personal genome testing.
The personal genome testing market size is further obstructed owing to standardization concerns of genetic testing-based diagnostics.
Furthermore, the unavailability of doctors and genetic counselors, along with closing of test-running laboratories leading to disruption, limitation and challenges during the pandemic, hampered the adoption of personal genome testing.
Scepticism and criticism regarding genetic testing from healthcare professionals, owing to lack of evidence, thwarts the personal genome testing market share.
The desire for personal genome testing is curbed by the loss of discretion and control over customers' genetic material, as well as the risk that testing procedures could lead to a third party accessing clients' DNA information.
Principal Consultant
Unexplored emerging markets in developing economies and a high number of customers opting for online genetic testing are anticipated to promote the global personal genome testing market growth.
Moreover, the adoption of personal genome testing increases owing to the growth in the personalized medicine market, especially among the pharmaceutical companies. The shift of focus from clinical science to bioinformatics, and the increasing popularity of these techniques, increases the demand for personal genome testing.
Increased efficiency, accuracy, and new innovations and techniques further propel the demand for personal genome testing.
North America holds the leading position in the personal genome testing market share, with a revenue of 37.3%.
This is owing to the rise in cases of genetic diseases and an increasing demand for technologically advanced medical equipment for treatment. The availability of a substantial number of key players dealing with genetic tests in this region surges the demand for personal genome testing.
High awareness about at-home testing among the U.S. population promotes the global personal genome testing market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Europe has the second leading personal genome testing market share, with a revenue share of 26%.
The rising demand for technologically advanced medical equipment for treatment in this region promotes personal genome testing market growth.
The presence of key players, as well as new players entering the market causing competition, secures the expansion of the personal genome testing market size.
Due to rising knowledge of the advantages of genetic testing, the personal genome testing market share is predicted to increase in Asia-Pacific. Personal genome testing is becoming more popular as a result of growing awareness of numerous genetic illnesses and an increase in their prevalence in this area.
Rapid development of healthcare infrastructures across Asian countries further promotes market growth.
Several market players, through research and development activities, are coming up with innovative strategies to refine genetic testing in clinics. They are also implementing schemes to protect the privacy of their clients’ DNA information.
Emerging players such as 3x4 Genetics, 3billion, CircaGene, Bione, Athletic Genetix, etc. are offering various services such as DNA-based fitness programs, genetic testing for rare diseases, personalized genetic test platforms, microbiome testing, genetic testing for athletes, etc.
Some of the key market participants in the personal genome testing market are 23andMe Inc., Navigenics, deCODEme, Color Genomics Inc., Personal Genome Diagnostics Inc., Counsyl, Inc., Quest Diagnostics, Gene By Gene Ltd., Laboratory Corporation of America Holdings, Thermo Fisher Scientific, QIAGEN N.V., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., BGI, MYRIAD GENETICS, INC. (MYRIAD RBM, INC.), Eurofins Scientific, CSL Ltd., Abbott Laboratories, Invitae Corporation, Ambry Genetics, BioReference, Progenity Inc., and others are coming up with new innovations to perfect the extraction of genetic material.
Rising cases of chronic diseases are increasing the adoption of personal genome testing. This is attributed to the growth of key players in the market, which is increasing competitiveness in the market, surging the demand for personal genome testing.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 10.1% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2015 to 2020 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD million and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
| Segments covered | Type, Application, and Region. |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand |
| Country scope | USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
| Key companies profiled | 23andMe Inc.; Navigenics; deCODEme; Color Genomics Inc.; Personal Genome Diagnostics Inc.; Counsyl, Inc.; Quest Diagnostics; Gene By Gene Ltd.; Laboratory Corporation of America Holdings; Thermo Fisher Scientific; QIAGEN N.V.; Agilent Technologies, Inc.; F. Hoffmann-La Roche Ltd.; Bio-Rad Laboratories Inc.; BGI; MYRIAD GENETICS, INC. (MYRIAD RBM, INC.); Eurofins Scientific; CSL Ltd.; Abbott Laboratories; Invitae Corporation; Ambry Genetics; BioReference; Progenity Inc.; Burning Rock Biotech Ltd.; Celera Group; PerkinElmer Inc.; Quest Diagnostics Inc.; ELITech Group; Roche Diagnostics Corp.; Applied Biosystems Inc.; Roche Molecular Diagnostics Inc.; Transgenomic Inc.; Color Genomics; EasyDNA; Family Tree DNA; Full Genome Corporation Inc.; Helix OpCo LLC; Karmagenes SA; Living DNA Ltd.; MyHeritage; 24 Genetics; The SkinDNA Company Pty Ltd; DNA Forensics Laboratory Pvt. Ltd. |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Ans. Personal genome testing is likely to register a CAGR of 10.1% during the forecast period.
North America is the leading personal genome testing market, with a revenue share of 37.3%.
By 2032, the market is likely to grow to a valuation of US$ 4,468 Mn.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Personal Genome Testing Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Personal Genome Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Application
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2022-2032
5.3.1. Neurological Disorders
5.3.2. Oncology
5.3.3. Metabolic Disorders
5.3.4. Autoimmune Disorders
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Application, 2017-2021
5.5. Absolute $ Opportunity Analysis By Application, 2022-2032
6. Global Personal Genome Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Product Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Product Type, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product Type, 2022-2032
6.3.1. Targeted Testing
6.3.2. Non-Targeted Testing
6.3.3. Multi-Targeted Testing
6.4. Y-o-Y Growth Trend Analysis By Product Type, 2017-2021
6.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032
7. Global Personal Genome Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Personal Genome Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Application
8.2.3. By Product Type
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Application
8.3.3. By Product Type
8.4. Key Takeaways
9. Latin America Personal Genome Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Application
9.2.3. By Product Type
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Application
9.3.3. By Product Type
9.4. Key Takeaways
10. Europe Personal Genome Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Application
10.2.3. By Product Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Application
10.3.3. By Product Type
10.4. Key Takeaways
11. Asia Pacific Personal Genome Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Malaysia
11.2.1.5. Singapore
11.2.1.6. Australia
11.2.1.7. Rest of Asia Pacific
11.2.2. By Application
11.2.3. By Product Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Application
11.3.3. By Product Type
11.4. Key Takeaways
12. MEA Personal Genome Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Application
12.2.3. By Product Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Application
12.3.3. By Product Type
12.4. Key Takeaways
13. Key Countries Personal Genome Testing Market Analysis
13.1. U.K.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Application
13.1.2.2. By Product Type
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Application
13.2.2.2. By Product Type
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Application
13.3.2.2. By Product Type
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Application
13.4.2.2. By Product Type
13.5. Rest of Latin America
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Application
13.5.2.2. By Product Type
13.6. Germany
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Application
13.6.2.2. By Product Type
13.7. U.K.
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Application
13.7.2.2. By Product Type
13.8. France
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Application
13.8.2.2. By Product Type
13.9. Spain
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Application
13.9.2.2. By Product Type
13.10. Italy
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Application
13.10.2.2. By Product Type
13.11. Rest of Europe
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Application
13.11.2.2. By Product Type
13.12. China
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Application
13.12.2.2. By Product Type
13.13. Japan
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Application
13.13.2.2. By Product Type
13.14. South Korea
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Application
13.14.2.2. By Product Type
13.15. Malaysia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Application
13.15.2.2. By Product Type
13.16. Singapore
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Application
13.16.2.2. By Product Type
13.17. Australia
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2021
13.17.2.1. By Application
13.17.2.2. By Product Type
13.18. Rest of Asia Pacific
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2021
13.18.2.1. By Application
13.18.2.2. By Product Type
13.19. GCC Countries
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2021
13.19.2.1. By Application
13.19.2.2. By Product Type
13.20. South Africa
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2021
13.20.2.1. By Application
13.20.2.2. By Product Type
13.21. Israel
13.21.1. Pricing Analysis
13.21.2. Market Share Analysis, 2021
13.21.2.1. By Application
13.21.2.2. By Product Type
13.22. Rest of MEA
13.22.1. Pricing Analysis
13.22.2. Market Share Analysis, 2021
13.22.2.1. By Application
13.22.2.2. By Product Type
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Application
14.3.3. By Product Type
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. 23andMe, Inc.
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Navigenics
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. deCODEme
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Color Genomics, Inc
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Personal Genome Diagnostics, Inc.
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Counsyl, Inc.
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Quest Diagnostics,
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Gene By Gene, Ltd.
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. aboratory Corporation of America® Holdings
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. mapmygenome.in
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
15.1.11. Positive Bioscience, Inc
15.1.11.1. Overview
15.1.11.2. Product Portfolio
15.1.11.3. Profitability by Market Segments
15.1.11.4. Sales Footprint
15.1.11.5. Strategy Overview
15.1.11.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Personal Genome Testing Market
